AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02281578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based combination HIV prevention intervention
Description: The combination package will include integrated biomedical, behavioral and structural components: (1) mobile HIV testing and risk reduction counseling; (2) service navigation to facilitate access to treatment and retention in care; (3) sensitivity training for HIV clinical care providers; (4) SMS text messages to promote adherence to care and ART; (5) venue-based peer education and condom distribution; and (6) a community drop-in-center to promote cohesion and collective action to reduce stigma and discrimination.
Study NCT02281578 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care HIV services
Description: Locally available standard of care HIV prevention, treatment and care services
Study NCT01912105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway medix closed suction system
Study NCT01912105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard closed suctioning systems
Study NCT03185897 — intervention group
Intervention type: OTHER
Intervention: Non-treatment, seroprevalence
Description: Non-treatment study examining the prevalence of preexisting immunity to adeno-associated virus (AAV)
Study NCT02196168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02196168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02196168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02196168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02196168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02196168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WEE1 Inhibitor AZD1775
Description: Given PO
Study NCT00634218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mail-based Self-help plus Internet-based Smoking Treatment
Description: Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants.
Study NCT00634218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Manual plus Telephone counseling
Description: Participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions. The counseling sessions focus on the development of a personalized plan to quit smoking and occur over a 3 month period.
Study NCT00634218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Manual
Description: Participants will receive a self-help smoking cessation manual specifically developed for LGBT smokers. The manual provides information on quitting smoking and encourages the development of a personalized quit plan through various activities and exercises.
Study NCT00634218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Manual plus Internet-based Intervention plus Telephone Counseling
Description: Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants. Smokers will also receive 6 telephone-based counseling sessions which occur over a 3 month period
Study NCT00998829 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants.
Study NCT03142828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Healing abutment with Clorhexidine
Study NCT03142828 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healing abutment without any antiseptic
Study NCT01916798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid infusion
Description: IV infusion of 250 ml of intralipid 20% solution at the day of Ovum pick up \& another dose at the day of embryo Transfer.
Study NCT05566509 — intervention group
Intervention type: PROCEDURE
Intervention: Breast excision
Description: some patient had minimal excision, some had maximal excision.
Study NCT01729923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT01729923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO
Study NCT01729923 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT01729923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01729923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01729923 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT01729923 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo stereotactic radiosurgery
Study NCT01729923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study NCT01252511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RYGB for surgical treatment of severe obesity
Description: Twenty severely obese patients who have been scheduled to receive long limb RYGB will be enrolled in the study. By randomization, 10 patients will have a biliopancreatic limb that includes 40 cm of jejunum and a Roux limb that contains 150 cm of jejunum. The other 10 patients will receive a biliopancreatic limb that contains 75 cm of jejunum and a Roux limb of 115 cm.
Study NCT01993576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery
Study NCT00812123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Loading dose 30 mg for three days, trough level of 10-20 ng/ml month 1-3, 8-15 ng/ml month 4 - 6
Study NCT00812123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A
Description: Loading dose of 300 mg for three days, trough levels 250-300 ng/ml months 1-3, 150-250 ng/ml months 4 to 6
Study NCT00812123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 0.5 mg/kg, tapering every two weeks until 0.1 mg/kg
Study NCT00812123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 0.5 mg/kg, tapering every two weeks until 0.1 mg/kg
Study NCT00812123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: 2 x 1000mg, through level above 2ug/ml
Study NCT00812123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 2 x 1000mg, through level above 2ug/ml
Study NCT00812123 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protocol biopsies
Description: protocol kidney biopsies at month one and three
Study NCT00812123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocol biopsies
Description: protocol kidney biopsies at month one and three
Study NCT01090700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 150 mg daily for 7 days
Study NCT01090700 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram
Description: Escitalopram 10 mg daily for 7 days
Study NCT01090700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 + Escitalopram
Description: TMC435 150 mg + escitalopram 10 mg daily for 7 days
Study NCT02582034 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Optimized Internal Radiation Therapy
Description: Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).~Optimized dosimetry arm: the activity to be administered is calculated so as to deliver predictive dosimetry:~* An absorbed dose to the tumor of at least ≥ 205 Gy and if possible exceeding 250 Gy or even 300 Gy~* A dose at the treated healthy liver \< 120 Gy in case of lobar treatment~* Dose to the treated healthy liver can exceed 120 Gy in case of segmental treatment and hepatic reserve > 30%~* A pulmonary dose \< 30 Gy for one treatment and \< 50 Gy in cumulative dose in case of multiple treatments.
Study NCT02582034 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Internal Radiation Therapy
Description: Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).Standard dosimetry arm: the activity to be administered is calculated so as predictive dosimetry:~* An absorbed dose of 120 ± 20 Gy to the treated volume (whatever the tumor absorbed dose)~* A pulmonary dose \< 30 Gy for one treatment and \< 50 Gy in cumulative dose in case of multiple treatments.
Study NCT04854902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Description: 1.5-2 x 5 x 10 mm size epithelialized graft harvested from the palate is stabilized in the mandibular anterior single-tooth recession region
Study NCT04854902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft
Description: 1.5-2 x 5 x 10 mm size epithelialized graft harvested from the palate is stabilized in the mandibular anterior single-tooth recession region
Study NCT04854902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate
Description: N-Butyl-Cyanoacryle is applied to stabilize the graft to the recipient bed and to coat the donor site wound
Study NCT04854902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: The graft is stabilized with 6/0 polyvinylidene fluoride suture to the recipient bed
Study NCT03560414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simple plasma exchange
Description: simple plasma exchange treatment
Study NCT03560414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional PDF treatment group
Description: conventional PDF treatment group
Study NCT03560414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: less plasma PDF treatment group
Description: less plasma Plasma diafiltration treatment
Study NCT01574014 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBGT
Description: Cognitive-behavioral group therapy
Study NCT01574014 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBGT
Description: Cognitive-behavioral group therapy
Study NCT01574014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: 3 x 20 mg Hydrocortisone (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
Study NCT01574014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
Study NCT00136175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT00136175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT00136175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01006447 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructor contact
Study NCT03795402 — intervention group
Intervention type: DEVICE
Intervention: Microneedle Device
Description: Microneedle device will be used for collecting skin samples as a non-invasive method.
Study NCT02383927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: FTase inhibitor
Study NCT02453516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Block
Description: Ultrasound-guided nerve block using ropivacaine 0.5% (0.4ml/kg) injected between the serratus anterior and external intercostal muscles
Study NCT02453516 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Block
Description: Subcutaneous injection of 1ml sterile normal saline solution in the midaxillary line
Study NCT02453516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Drug indicated for regional anesthesia
Study NCT02453516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine
Description: Drug indicated to prolong the action of regional anesthesia
Study NCT02453516 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline
Description: Neutral injection (no drug involved)
Study NCT01121185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MBL-HCV1
Description: 50 mg/kg MBL-HCV1, intravenous
Study NCT01121185 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium chloride Placebo
Description: 0.9% sodium chloride, intravenous
Study NCT01431105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin dose titration to maximum tolerated dose (once daily for 6 weeks)
Study NCT01133925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Sprint
Description: Zotarolimus Eluting Stent (Resolute Sprint) implanted in overlap
Study NCT01133925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus Eluting Stent
Description: Cypher stents implanted in overlap
Study NCT01133925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel Eluting Stent
Description: Taxus stents implanted in overlap
Study NCT01133925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus eluting stent
Description: Endeavor stents implanted in overlap
Study NCT03246399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690
Description: suspension formulation of SM04690, delivered via intradiscal injection (single injection)
Study NCT03397316 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: xenograft placement .
Description: immediate implant placement in upper esthetic zone with xenograft placement between residual labial bone and implant surface.
Study NCT00402636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rapamycin plus 17beta estradiolvalerat-eluting stent
Description: rapamycin plus 17beta estradiolvalerat-eluting stent was implanted due to randomisation
Study NCT00402636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rapamycin-eluting stent
Description: rapamycin-eluting stent was implanted due to randomisation
Study NCT02618863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cricoid pressure
Description: Applying cricoid pressure and testing its effectiveness using gastric tube . in addition , by using the cricometer , the CP 50 is defined and compared in both gender
Study NCT02928809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: Three points will be irradiated over the masseter muscle (upper, middle and lower bundles) and one point will be irradiated over the anterior temporal muscle of each side of the face in the groups submitted to pre-fatigue laser. The following parameters will be employed: wavelength: 780 nm; energy density: 25 J/cm2; output power: 50 mW; power density: 1.25 W/cm2; and exposure time: 20 seconds per points, resulting in a total energy of 1 J per point. The laser will be applied punctually with a conventional tip in contact with the skin considering an area of 0.04 cm2.
Study NCT02928809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: The same equipment will be used in the placebo group, but with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
Study NCT03427008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: The mHealth app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
Study NCT01849913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser
Description: The laser will be used 830 nm, 30 milliwatts twice a week: the initial dosage will be 5.9 J per point. The irradiation will be performed bilaterally on the belly of the trapezius muscle as well as 2 cm to the right and left and 2 and 4 cm below the belly of the muscle.
Study NCT01849913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To provide the blinding: the laser equipment has two identical application points furnished by the manufacturer - one active and the other a placebo (does not emit energy).
Study NCT03477825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Group A: Placebo group (n = 10)~* Supplement appearing similar to Herbal formulations~* Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~* Dose: subjects in this group will take 4 placebo tablets per day
Study NCT03477825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rubia Cordifolia
Description: Group B: R. cordifolia group (n = 10)~* 2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)~* Each tablet contains 500 mg of R. cordifolia per tablet.
Study NCT03477825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Triphala
Description: Group C: Triphala group (n= 10)~* Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)~* Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula~* Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb.
Study NCT01091519 — intervention group
Intervention type: OTHER
Intervention: Toviaz(fesoterodine) plus educational materials
Description: Educational materials including the Self-Assessment Goal Achievement (SAGA) tool to support dialogue.
Study NCT01091519 — intervention group
Intervention type: OTHER
Intervention: Toviaz(fesoterodine) without educational materials
Description: No educational materials
Study NCT02647645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of 20 minutes each for 6 sessions over two weeks simultaneously with cognitive training.
Study NCT02647645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Computer delivered intervention designed to improve cognitive speed and executive functioning for a period of 20 minutes each for 6 sessions over two weeks.
Study NCT02647645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Computer delivered intervention designed to improve cognitive speed and executive functioning for a period of 20 minutes each for 6 sessions over two weeks.
Study NCT02647645 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of one minute to simulate active treatment applied in 6 sessions over two weeks.
Study NCT03524768 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: skin laser speckle contrast imaging and video-capillaroscopy
Description: Evaluation of endothelial-dependent microvascular reactivity and capillary recruitment
Study NCT00097669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo
Description: multivitamin
Study NCT00097669 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05646966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: one time testing
Study NCT03146871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT03146871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT03146871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies